Category Archives: Molecular Medicine

Share

Share

Share

Email

Thailand, August 28, 2017 An investigation is launched in Thailand after a woman fell from the 31stfloor of a hotel to her death, that woman is a Turks and Caicos Islander identified as #MaxineVerniceMissick. Missick was a medical student studying at Keele University in the UK but was on a trip to Thailand when she somehow plunged to her death and was found in an alley between two hotels with a broken neck and other broken bones around 5am Friday.

The 23 year old is a graduate of Clement Howell High, and had reportedly been accepted recently to work at the Institute for Molecular Medicine Research in Penang, Malaysia. Police explained that her room was not ransacked, that her hotel room door was locked and that Missick checked in, alone and arrived in the country on August 18. Her hotel check out date was August 31.

Friends of Maxine, who was described as a British citizen in news reports out of Thailand is also Haitian and was called a woman who loved the Lord, loved African culture, always had a smile on her face and loved meeting people.

Police in Thailand have not ruled out suicide, promise a thorough investigation and say an autopsy will be performed to determine exact cause of death. Condolences to Maxines friends and family.

#MagneticMediaNews

More here:
TCI woman fell 31 floors, due to work in molecular medicine in Malaysia - Magnetic Media (press release)

The Graduate Program in Molecular Medicine at the University of Maryland Baltimore offers research and training opportunities with internationally-renowned scientists. Our Molecular Medicine Program is an interdisciplinary program of study leading to a Ph.D. degree. There are four different research tracks: Cancer Biology, Genome Biology, Molecular and Cell Physiology, and Toxicology and Pharmacology. Each provides for a unique interdisciplinary research and graduate training experience that is ideally suited for developing scientists of the post-genomic era.

Faculty mentors in this graduate program are leaders in their respective research areas and reside in various departments and Organized Research Centers in the School of Medicine and Dental School, the Institute for Genomic Sciences (IGS), the Institute of Human Virology (IHV), the Marlene and Stewart Greenebaum Cancer Center, and the Center for Vascular and Inflammatory Diseases (CVID). The over 150 faculty in the Graduate Program in Molecular Medicine are internationally recognized for their research in biotechnology, cancer, cardiovascular and renal biology, functional genomics and genetics, membrane biology, muscle biology, neuroscience and neurotoxicology, reproduction and vascular biology.

Read more here:
Molecular Medicine | University of Maryland School of Medicine

Next month, the Michigan State University College of Human Medicine will open a new research facility in Grand Rapids.

WKAR's Scott Pohl reports on the new MSU Grand Rapids Research Center, opening in September.

For almost a decade, MSU has leased research space in Grand Rapids from the Van Andel Institute. This new building is the former site of the Grand Rapids Press newspaper. Demolition of that building and the construction of a six-story, 162,800 square foot research center came with a price tag of just over $88-million dollars. Donors include Richard and Helen DeVos, who gave $10-million, and Peter and Joan Secchia, who contributed another $5-million. Other money is coming from the MSU general fund and from tax exempt financing.

MSU College of Human Medicine Dean Dr. Norman Beauchamp credits university President Lou Anna Simon for bringing this dream to life. "The process of creating this really was the university president having a vision for strengthening the research at Michigan State University and having a passion for what we could do to improve health," Dr. Beauchamp states.

MSU research into Parkinsons disease, Alzheimers disease and traumatic brain injury will move here from the Van Andel Institute. Dr. Jack Lipton, chair of Translational Science and Molecular Medicine, says the move will enhance their work. "We were promised when we first came here in 2009 that a building was eventually going to go up," Dr. Lipton explains. "We've been hosted by the Van Andel (Institute) for a few years, and that's been great, but we didn't have the ability to expand. This building is now an extension of the main campus."

Research into womens cancers, prenatal and infant development and infertility will also move to the new facility next month. Obstetrics, Gynecology and Reproductive Biology Chair Dr. Richard Leach says his department has grown from just one researcher in Grand Rapids to a current total of 12. He continues that "this facility enables us to not only bring in state of the art equipment, but the design of this facility enables us to bring our researchers together in teams."

The move wont be done all at once. Certain experiments cant simply be relocated down the street; some researchers will wrap up projects at the Van Andel Institute before occupying space in the new facility.

The MSU Grand Rapids Research Center has scheduled a dedication ceremony for September 20th.

Originally posted here:
MSU Expanding Medical Research In Grand Rapids | WKAR - WKAR

PET scan of a human brain with Alzheimer's disease. Credit: public domain

A gene called triggering receptor expressed on myeloid cells 2, or TREM2, has been associated with numerous neurodegenerative diseases, such as Alzheimer's disease, Frontotemporal lobar degeneration, Parkinson's disease, and Nasu-Hakola disease. Recently, a rare mutation in the gene has been shown to increase the risk for developing Alzheimer's disease.

Independently from each other, two research groups have now revealed the molecular mechanism behind this mutation. Their research, published today in EMBO Molecular Medicine, sheds light on the role of TREM2 in normal brain function and suggests a new therapeutic target in Alzheimer's disease treatment.

Alzheimer's disease, just like other neurodegenerative diseases, is characterized by the accumulation of specific protein aggregates in the brain. Specialized brain immune cells called microglia strive to counter this process by engulfing the toxic buildup. But as the brain ages, microglia eventually lose out and fail to rid all the damaging material.

TREM2 is active on microglia and enables them to carry out their protective function. The protein spans the microglia cell membrane and uses its external region to detect dying cells or lipids associated with toxic protein aggregates. Subsequently, TREM2 is cut in two. The external part is shed from the protein and released, while the remaining part still present in the cell membrane is degraded. To better understand TREM2 function, the two research groups took a closer look at its cleavage. They were led by Christian Haass at the German Center for Neurodegenerative Diseases at the Ludwig-Maximilians-Universitt in Munich, Germany, and Damian Crowther of AstraZeneca's IMED Neuroscience group in Cambridge, UK together with colleagues at the Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto and the Cambridge Institute for Medical Research, University of Cambridge, UK.

Using different technological approaches, both groups first determined the exact site of protein shedding and found it to be at amino acid 157. Amino acid 157 was no unknown. Only recently, researchers from China had uncovered that a mutation at this exact position, referred to as p.H157Y, increased the risk of Alzheimer's disease. Together, these observations indicate that protein cleavage is perturbed in the p.H157 mutant and that this alteration promotes disease development.

As a next step, Haass and Crowther's groups investigated the biochemical properties of the p.H157Y mutant protein more closely. They found that the mutant was cleaved more rapidly than a healthy version of the protein. "Our results provide a detailed molecular mechanism for how this rare mutation alters the function of TREM2 and hence facilitates the progression of Alzheimer's disease," said Crowther.

While most TREM2 mutations affect protein production, the mechanism behind p.H157Y is somewhat different. The p.H157Y mutation allows the protein to be correctly manufactured and transported to the microglia cell surface, but then it is cleaved too quickly. "The end result is the same. In both cases, there is too little full-length TREM protein on microglia," said Haass. "This suggests that stabilizing TREM2, by making it less susceptible to cleavage, may be a viable therapeutic strategy."

Explore further: Phagocytes in the braingood or bad?

More information: TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant EMBO Molecular Medicine, DOI: 10.15252/emmm.201707673

Link:
Stabilizing TREM2 a potential strategy to combat Alzheimer's disease - Medical Xpress

Scientists at the University of Oxford have developed a new method to 3D-print laboratory- grown cells to form living structures.

The approach could revolutionise regenerative medicine, enabling the production of complex tissues and cartilage that would potentially support, repair or augment diseased and damaged areas of the body.

In research published in the journal Scientific Reports, an interdisciplinary team from the Department of Chemistry and the Department of Physiology, Anatomy and Genetics at Oxford and the Centre for Molecular Medicine at Bristol, demonstrated how a range of human and animal cells can be printed into high-resolution tissue constructs.

Interest in 3D printing living tissues has grown in recent years, but, developing an effective way to use the technology has been difficult, particularly since accurately controlling the position of cells in 3D is hard to do.

They often move within printed structures and the soft scaffolding printed to support the cells can collapse on itself.

As a result, it remains a challenge to print high-resolution living tissues. But, led by Professor Hagan Bayley, Professor of Chemical Biology in Oxfords Department of Chemistry, the team devised a way to produce tissues in self-contained cells that support the structures to keep their shape.

The cells were contained within protective nanolitre droplets wrapped in a lipid coating that could be assembled, layer-by-layer, into living structures.

Producing printed tissues in this way improves the survival rate of the individual cells, and allowed the team to improve on current techniques by building each tissue one drop at a time to a more favourable resolution.

To be useful, artificial tissues need to be able to mimic the behaviours and functions of the human body. The method enables the fabrication of patterned cellular constructs, which, once fully grown, mimic or potentially enhance natural tissues.

Dr Alexander Graham, lead author and 3D Bioprinting Scientist at OxSyBio (Oxford Synthetic Biology), said: We were aiming to fabricate three-dimensional living tissues that could display the basic behaviours and physiology found in natural organisms. To date, there are limited examples of printed tissues, which have the complex cellular architecture of native tissues. Hence, we focused on designing a high-resolution cell printing platform, from relatively inexpensive components, that could be used to reproducibly produce artificial tissues with appropriate complexity from a range of cells including stem cells.

The researchers hope that, with further development, the materials could have a wide impact on healthcare worldwide. Potential applications include shaping reproducible human tissue models that could take away the need for clinical animal testing.

The team completed their research last year, and have since taken steps towards commercialising the technique and making it more widely available. In January 2016, OxSyBio officially spun-out from the Bayley Lab. The company aims to commercialise the technique for industrial and biomedical purposes.

Over the coming months they will work to develop new complementary printing techniques, that allow the use of a wider range of living and hybrid materials, to produce tissues at industrial scale. Dr Sam Olof, Chief Technology Officer at OxSyBio, said: There are many potential applications for bioprinting and we believe it will be possible to create personalised treatments by using cells sourced from patients to mimic or enhance natural tissue function. In the future, 3D bio-printed tissues maybe also be used for diagnostic applications for example, for drug or toxin screening.

Dr Adam Perriman from the University of Bristols School of Cellular and Molecular Medicine, added: The bioprinting approach developed with Oxford University is very exciting, as the cellular constructs can be printed efficiently at extremely high resolution with very little waste. The ability to 3D print with adult stem cells and still have them differentiate was remarkable, and really shows the potential of this new methodology to impact regenerative medicine globally

The full citation for the paper is High-resolution patterned cellular constructs by droplet-based 3D printingA.D. Graham et. al. Scientific Reports 7, Article number: 7004 (2017).

Excerpt from:
New method for the 3D printing of living tissues - Scientist Live

What if one day, we could teach our bodies to self-heal like a lizards tail, and make severe injury or disease no more threatening than a paper cut?

Or heal tissues by coaxing cells to multiply, repair or replace damaged regions in loved ones whose lives have been ravaged by stroke, Alzheimers or Parkinsons disease?

Such is the vision, promise and excitement in the burgeoning field of regenerative medicine, now a major ASU initiative to boost 21st-century medical research discoveries.

ASU Biodesign Institute researcher Nick Stephanopoulos is one of several rising stars in regenerative medicine. In 2015, Stephanopoulos, along with Alex Green and Jeremy Mills, were recruited to the Biodesign Institutes Center for Molecular Design and Biomimetics (CMDB), directed by Hao Yan, a world-recognized leader in nanotechnology.

One of the things that that attracted me most to the ASU and the Biodesign CMDB was Haos vision to build a group of researchers that use biological molecules and design principles to make new materials that can mimic, and one day surpass, the most complex functions of biology, Stephanopoulos said.

I have always been fascinated by using biological building blocks like proteins, peptides and DNA to construct self-assembled structures, devices and materials, and the interdisciplinary and highly collaborative team in the CMDB is the ideal place to put this vision into practice.

Yans research center uses DNA and other basic building blocks to build their nanotechnology structures only at a scale 1,000 times smaller than the width of a human hair.

Theyve already used nanotechnology to build containers to specially deliver drugs to tissues, build robots to navigate a maze or nanowires for electronics.

To build a manufacturing industry at that tiny scale, their bricks and mortar use a colorful assortment of molecular Legos. Just combine the ingredients, and these building blocks can self-assemble in a seemingly infinite number of ways only limited by the laws of chemistry and physics and the creative imaginations of these budding nano-architects.

Learning from nature

The goal of the Center for Molecular Design and Biomimetics is to usenatures design rulesas an inspiration in advancing biomedical, energy and electronics innovation throughself-assembling moleculesto create intelligent materials for better component control and for synthesis intohigher-order systems, said Yan, who also holds the Milton Glick Chair in Chemistry and Biochemistry.

Prior to joining ASU, Stephanopoulos trained with experts in biological nanomaterials, obtaining his doctorate with the University of California Berkeleys Matthew Francis, and completed postdoctoral studies with Samuel Stupp at Northwestern University. At Northwestern, he was part of a team that developed a new category of quilt-like, self-assembling peptide and peptide-DNA biomaterials for regenerative medicine, with an emphasis in neural tissue engineering.

Weve learned from nature many of the rules behind materials that can self-assemble. Some of the most elegant complex and adaptable examples of self-assembly are found in biological systems, Stephanopoulos said.

Because they are built from the ground-up using molecules found in nature, these materials are also biocompatible and biodegradable, opening up brand-new vistas for regenerative medicine.

Stephanopoulos tool kit includes using proteins, peptides, lipids and nucleic acids like DNA that have a rich biological lexicon of self-assembly.

DNA possesses great potential for the construction of self-assembled biomaterials due to its highly programmable nature; any two strands of DNA can be coaxed to assemble to make nanoscale constructs and devices with exquisite precision and complexity, Stephanopoulos said.

Proof all in the design

During his time at Northwestern, Stephanopoulos worked on a number of projects and developed proof-of-concept technologies for spinal cord injury, bone regeneration and nanomaterials to guide stem cell differentiation.

Now, more recently, in a new studyin Nature Communications, Stephanopoulos and his colleague Ronit Freeman in the Stupp laboratory successfully demonstrated the ability to dynamically control the environment around stem cells, to guide their behavior in new and powerful ways.

In the new technology, materials are first chemically decorated with different strands of DNA, each with a unique code for a different signal to cells.

To activate signals within the cells, soluble molecules containing complementary DNA strands are coupled to short protein fragments, called peptides, and added to the material to create DNA double helices displaying the signal.

By adding a few drops of the DNA-peptide mixture, the material effectively gives a green light to stem cells to reproduce and generate more cells. In order to dynamically tune the signal presentation, the surface is exposed to a soluble single-stranded DNA molecule designed to grab the signal-containing strand of the duplex and form a new DNA double helix, displacing the old signal from the surface.

This new duplex can then be washed away, turning the signal off. To turn the signal back on, all that is needed is to now introduce a new copy of single-stranded DNA bearing a signal that will reattach to the materials surface.

One of the findings of this work is the possibility of using the synthetic material to signal neural stem cells to proliferate, then at a specific time selected by the scientist, trigger their differentiation into neurons for a while, before returning the stem cells to a proliferative state on demand.

One potential use of the new technology to manipulate cells could help cure a patient with neurodegenerative conditions like Parkinsons disease.

The patients own skin cells could be converted to stem cells using existing techniques. The new technology could help expand the newly converted stem cells back in the lab and then direct their growth into specific dopamine-producing neurons before transplantation back to the patient.

People would love to have cell therapies that utilize stem cells derived from their own bodies to regenerate tissue, Stupp said. In principle, this will eventually be possible, but one needs procedures that are effective at expanding and differentiating cells in order to do so. Our technology does that.

In the future, it might be possible to perform this process entirely within the body. The stem cells would be implanted in the clinic, encapsulated in the type of material described in the new work, and injected into a particular spot. Then the soluble peptide-DNA molecules would be given to the patient to bind to the material and manipulate the proliferation and differentiation of transplanted cells.

Scaling the barriers

One of the future challenges in this area will be to develop materials that can respond better to external stimuli and reconfigure their physical or chemical properties accordingly.

Biological systems are complex, and treating injury or disease will in many cases necessitate a material that can mimic the complex spatiotemporal dynamics of the tissues they are used to treat, Stephanopoulos said.

It is likely that hybrid systems that combine multiple chemical elements will be necessary; some components may provide structure, others biological signaling and yet others a switchable element to imbue dynamic ability to the material.

A second challenge, and opportunity, for regenerative medicine lies in creating nanostructures that can organize material across multiple length scales. Biological systems themselves are hierarchically organized: from molecules to cells to tissues, and up to entire organisms.

Consider that for all of us, life starts simple, with just a single cell. By the time we reach adulthood, every adult human body is its own universe of cells, with recent estimates of 37 trillion or so. The human brain alone has 100 billion cells or about the same number of cells as stars in the Milky Way galaxy.

But over the course of a life, or by disease, whole constellations of cells are lost due to the ravages of time or the genetic blueprints going awry.

Collaborative DNA

To overcome these obstacles, much more research funding and recruitment of additional talent to ASU will be needed to build the necessary regenerative medicine workforce.

Last year, Stephanopoulos research received a boost with funding from the U.S. Air Forces Young Investigator Research Program (YIP).

The Air Force Office of Scientific ResearchYIP award will facilitate Nicks research agenda in this direction, and is a significant recognition of his creativity and track record at the early stage of his careers, Yan said.

Theyll need this and more to meet the ultimate challenge in the development of self-assembled biomaterials and translation to clinical applications.

Buoyed by the funding, during the next research steps, Stephanopoulos wants to further expand horizons with collaborations from other ASU colleagues to take his research teams efforts one step closer to the clinic.

ASU and the Biodesign Institute also offer world-class researchers in engineering, physics and biology for collaborations, not to mention close ties with the Mayo Clinic or a number of Phoenix-area institutes so we can translate our materials to medically relevant applications, Stephanopoulos said.

There is growing recognition that regenerative medicine in the Valley could be a win-win for the area, in delivering new cures to patients and building, person by person, a brand-new medicinal manufacturing industry.

Stephanopoulos recent research was carried out at Stupps Northwesterns Simpson Querrey Institute for BioNanotechnology. The National Institute of Dental and Craniofacial Research of the National Institutes of Health (grant 5R01DE015920) provided funding for biological experiments, and the U.S. Department of Energy, Office of Science, Basic Energy Sciences provided funding for the development of the new materials (grants DE-FG01-00ER45810 and DE-SC0000989 supporting an Energy Frontiers Research Center on Bio-Inspired Energy Science (CBES)).

The paper is titled Instructing cells with programmable peptide DNA hybrids. Samuel I. Stupp is the senior author of the paper, and post-doctoral fellows Ronit Freeman and Nicholas Stephanopoulos are primary authors.

More:
Bio-inspired Materials Give Boost to Regenerative Medicine - Bioscience Technology

The Section on Molecular Medicinefocuses on performing cutting-edge research in cellular and molecularmechanisms of human disease and supports graduate and postgraduate leveleducational programs within the Department of Internal Medicine. The Sectionserves as the administrative home for the largest PhD graduate program(Molecular Medicine and Translational Science) in the Biomedical Sciences atWake Forest University and an NIH-sponsored institutional predoctoral trainingprogram (T-32) in Integrative Lipid Sciences, Inflammation, and ChronicDiseases.

A major goal of the section is toserve as a nidus for translational research by providing an environment whereclinical and basic science faculty interact to make new discoveries and toeducate future scientists.

The section consists of ten (10) primary faculty members and one (1) Emeritus faculty member who use cellular and molecular approaches to gain abetter understanding of the basic mechanisms underlying several chronic humanconditions including: asthma, atherosclerosis, hepatosteatosis, obesity andinsulin resistance, autoimmunity, and age-related pathology (arthritis,Alzheimers disease).

A particular research focus isthe role of inflammation in the pathogenesis of acute and chronic humandiseases. Faculty research strengths are in areas of cell signaling, cellbiology, proteomics, regulation of gene expression, and the use of genetically-modifiedmouse models of human disease. The research in the section is supported bygrants from the NIH, from the Department of Defense, from foundations including the Avon Foundation and theAmerican Heart Association, and from partnerships with industry.

The section also provides acenter for laboratory research training and education in translational researchfor medical students, residents, and postdoctoral fellows includingsubspecialty fellows in the Department of Internal Medicine. A seminar seriesis held weekly in conjunction with the graduate program in Molecular Medicineand Translation Science.

John S. Parks, PhDProfessor of Internal Medicine, Biochemistry, and Translational ScienceChief, Section on Molecular Medicine

Molecular Medicine Journal Club

Faculty News

Originally posted here:
Molecular Medicine Research - Wake Forest School of Medicine

URBANDALE, Iowa, Aug. 16, 2017 /PRNewswire/ --Spotlight Innovation Inc. (OTCQB: STLT) today announced that the Company has entered into a Sponsored Research Agreement with Indiana University to support research directed by Elliot Androphy, M.D., aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy (SMA). Dr. Androphy is a member of Spotlight Innovation's Scientific Advisory Board and a co-inventor of STL-182, the Company's lead product candidate for SMA.

Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Dr. Androphy is a prolific researcher and highly-respected thought leader. We are privileged to work with him to develop novel therapies for SMA."

Dr. Androphy is the Chair of the Department of Dermatology of Indiana University School of Medicine and has published widely in high-impact journals including Science, Nature, EMBO Molecular Medicine, Human Molecular Genetics, Journal of Virology, and Molecular Cell. He served as Vice Chair for Research of the Department of Medicine and Director of the M.D./Ph.D. Program at the University of Massachusetts Medical School where his lab characterized the disease-causing mechanism of alternative splicing of the SMN2 gene. At Indiana University School of Medicine, Dr. Androphy has used a novel, cell-based high throughput screen for compounds that increase levels of the SMN protein. This work has led to the identification of pre-clinical drug candidates for SMA.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. Whenscientifically significantbenchmarkshave been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit http://www.spotlightinnovation.com or follow us on http://www.twitter.com/spotlightinno.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize various product candidates, including STL-182, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of STL-182; the inability to hire appropriate staff to develop STL-182; unforeseen technical difficulties in developing STL-182; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

View original content with multimedia:http://www.prnewswire.com/news-releases/spotlight-innovation-enters-into-sponsored-research-agreement-with-indiana-university-to-develop-new-therapies-for-spinal-muscular-atrophy-300505024.html

SOURCE Spotlight Innovation Inc.

Continued here:
Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for ... - Markets Insider

International students are encouraged to attend NTNU'sOrientation Week14 - 20 August 2017.

OnMonday 21 August at 10:15there will be a welcome meeting for all new master's students at the Faculty of Medicine and Health Sciences. This meeting takes place in auditorium KA12 in theKnowledge Centre at Campus ya.

After the welcome meeting (Monday 21 August at 12:00)there will be an orientation meeting for the MSc in Molecular Medicine. This meeting takes place in room Ls42 in the Laboratory Centre at Campus ya. It iscompulsory to attendthis meeting.

The field of molecular medicine is often referred to as "tomorrow's medicine". It aims to provide a molecular understanding of how normal cellular processes change, fail or are destroyed by disease. The purpose of the MSc programme is to develop knowledge and skills in cellular and molecular biology. These have applications in both research and practical clinical work, and will contribute to an increased understanding of processes, diagnostics and treatment of diseases.

The application deadline for for applicants from non-EU/non-EEA students is 1 December. The application deadline for students from EU/EEA countries is 1 March. You submit your application electronically.

The MSc in Molecular Medicine qualifies graduates for a wide range of careers, including practical clinical work and technical executive positions in hospital laboratories, and positions in pharmaceuticals and MedTech/BioTech companies.

The MSc is a two-year, full-time programme starting in the autumn semester. There are two main components: a master's thesis worth 60 credits, and theoretical and methodological courses totalling a further 60 credits.

Contact one of our student counsellors if you have any questions about the MSc programme. Email: lbk-post@medisin.ntnu.no / Telephone: +47 72 82 07 00

Continue reading here:
Master of Science (MSc) in Molecular Medicine - NTNU

The Master of Science in Molecular Medicine (MMED) program provides training in the academic, research and entrepreneurial aspects of the biomedical sciences with an emphasis on translational research in the development of therapeutics and vaccines.

Participation in the program will provide enhanced educational credentials through a flexible curriculum, with most classes offered in the early evening to maximize accessibility. Classes can be attended at two Drexel University College of Medicine locations: Center City and Queen Lane Campuses in Philadelphia. State-of-the-art videoconferencing provides real-time interactive learning at both locations.The program now can also be completed online, with all required courses and many elective courses available.

The Master of Science in Molecular Medicine program is designed to provide academic and practical biotechnological knowledge in translational research, particularly in the areas of molecular therapeutics and vaccine development.

If you prefer an online learning experience, you can still earn a Drexel master's degree in the field of molecular medicine. The online Master of Science in Molecular Medicine program features the same curriculum, flexibility, course content, and instructors as the traditional, face-to-face degree program.

Learn more about the online Master of Science in Molecular Medicine program!

In addition to broad geographic access, the curriculum provides flexibility in content and course load. Most students will complete the program in two years through completion of required courses and electives selected from two menus: research theory and laboratory research. The research experience can be in an academic environment or a company setting, as best fits the individual student's goals and interests.Some students may opt to complete the program on a part-time basis, taking up to four years. In either sequence, no dissertation is required. Program directors and course faculty will work closely with each student to best achieve his or her specific goals.

Learn more about the curriculum

The molecular medicine program is ideally suited for enhancing the scientific credentials of the following groups:

Read the original post:
MS in Molecular Medicine - Drexel University College of ...